Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, alone or in combination with other agents, in Participants with Advanced Tumors
Study of GSK3901961 and GSK3845097 in Patients with Synovial Sarcoma or Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Glaxo Smith Kline GSK
Enrolling: Male and Female Patients
IRB Number: AAAU1209
U.S. Govt. ID: NCT04526509
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to study the safety and efficacy of GSK3901961 and GSK3845097 when used to treat synovial sarcoma or non-small cell lung cancer and to examine if your tumor affects how the study drug works. You will need to receive chemotherapy for 3 to 4 days (depending on your age and your medical condition) before you are given GSK3901961 or GSK3845097. This is the first time these drugs have been used in humans. No people have ever been treated with GSK3901961 or GSK3845097. After your infusion of GSK3901961 or GSK3845097 you will be hospitalized.
Investigator
Matthew Ingham, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Are you able to give a sample of tumor tissue specimen archived or fresh biopsy? Yes No
Have you been diagnosed with advanced (metastatic or unresectable) synovial sarcoma or stage IV non-small cell lung cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162